natgillin/translations-raw huggingface dataset:
Because ProQuad contains well known weakened viruses, which are already used in other vaccines, the company presented data from vaccines that are already on the market. 
Ker cepivo ProQuad vsebuje dobro znane oslabljene viruse, ki se že uporabljajo v drugih cepivih, je družba predstavila podatke o cepivih, ki so že na trgu.
The full EPAR for ProQuad can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za cepivo ProQuad je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This study looked at the ability of the vaccine to trigger immune responses in these age groups. 
V tej študiji so proučevali sposobnost cepiva za sprožitev imunskega odziva v omenjenih starostnih skupinah otrok.
Other information about ProQuad 
Druge informacije o zdravilu ProQuad
ProQuad is a vaccine. 
Zdravilo ProQuad je cepivo.
This is a summary of the European public assessment report (EPAR) for ProQuad. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo ProQuad.
The active substances are attenuated (weakened) viruses for the diseases. 
Zdravilne učinkovine so atenuirani (oslabljeni) virusi za navedene bolezni.
For more information about treatment with ProQuad, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom ProQuad preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It is only given under the skin in patients with low levels of platelets in the blood or other bleeding disorders, as they may experience bleeding if the vaccine is injected into a muscle. 
Pod kožo se daje samo osebam, ki imajo nizke ravni krvnih ploščic ali druge motnje strjevanja krvi, saj lahko pride do krvavitve, če se cepivo injicira v mišico.
When a person is given the vaccine, the immune system recognises the weakened viruses as ‘foreign' and makes defences against them. 
Ko oseba prejme cepivo, imunski sistem prepozna oslabljene viruse kot „tujke“ in proti njim vzpostavi obrambni mehanizem.
ProQuad is used according to official recommendations, including the number of doses and the interval between them. 
Cepivo ProQuad se uporablja v skladu z uradnimi priporočili, kar velja tudi za število odmerkov in časovni razmik med njimi.
The vaccine is injected into a muscle or under the skin, preferably in the thigh in younger children and in the shoulder area in older children and adults. 
Cepivo se injicira v mišico ali pod kožo, po možnosti v stegensko mišico pri mlajših otrocih ter v ramensko območje pri starejših otrocih in odraslih.
A study has also been carried out with ProQuad in 1,620 children who received the first dose at 9, 11 and 12 months of age, and the second dose three months later. 
S cepivom ProQuad je bila izvedena tudi študija pri 1 620 otrocih, ki so prejeli prvi odmerek pri starosti 9, 11 in 12 mesecev, drugi odmerek pa tri mesece kasneje.
Another study also looked at the responses one year after vaccination in 2,108 children. 
V drugi študiji so pri 2 108 otrocih proučevali tudi odzive eno leto po cepljenju.
In the future, the immune system will be able to respond more quickly when it is exposed to the viruses again. 
Ob ponovni izpostavitvi virusom v prihodnosti se bo imunski sistem hitreje odzval nanje.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ProQuad. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo ProQuad, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
However, children who received the first dose at nine months of age had a lower immune response against measles. 
Vendar pa so otroci, ki so prvi odmerek prejeli v 9. mesecu starosti, imeli manjši imunski odziv proti ošpicam.
What benefit has ProQuad shown during the studies? 
Kakšne koristi je zdravilo ProQuad izkazalo med študijami?
The CHMP decided that ProQuad's benefits are greater than its risks and recommended that it be given marketing authorisation for use in children above 12 months of age, noting that a second vaccination against chickenpox should be given for full protection against the disease. 
CHMP je zaključil, da so koristi cepiva ProQuad večje od z njim povezanih tveganj in priporočil, da se zanj odobri dovoljenje za promet za uporabo pri otrocih, starejših od 12 mesecev, pri čemer je proti noricam potreben drugi odmerek cepiva, da se zagotovi popolna zaščita proti tej bolezni.
The most common side effect with ProQuad (seen in more than 1 patient in 10) are fever, and pain and erythema (redness) at the site of injection. 
Najpogostejši neželeni učinki cepiva ProQuad (opaženi pri več kot 1 od 10 bolnikov) so povišana telesna temperatura in bolečina ter eritem (pordelost) na mestu injiciranja.
What is the risk associated with ProQuad? 
Kakšna tveganja so povezana z zdravilom ProQuad?
The response rates in children above 12 months of age (measuring how the immune system had responded to the viruses) were: 98% for measles, 96% to 99% for mumps, 96% for rubella and 91% for chickenpox. 
Stopnje odziva pri otrocih, starejših od 12 mesecev (merilo odzivnosti imunskega sistema na viruse), so bile: 98 % pri ošpicah, od 96 % do 99 % pri mumpsu, 96 % pri rdečkah in 91 % pri noricah.
After the second dose, the rates were around 99% for measles, 100% for mumps, 98% for rubella, and 99% for chickenpox. 
Po drugem odmerku so bile stopnje odziva 99 % pri ošpicah, 100 % pri mumpsu, 98 % pri rdečkah in 99 % pri noricah.
The study in children from nine to 12 months of age showed that, after two doses of ProQuad, the immune response against mumps, rubella and chickenpox in children who received the first dose at nine months of age was comparable with those who received the first dose at 12 months of age. 
Študija pri otrocih, starih od 9 do 12 mesecev, je pokazala, da je bil po dveh odmerkih cepiva ProQuad imunski odziv proti mumpsu, rdečkam in noricam pri otrocih, ki so prvi odmerek prejeli v 9. mesecu starosti, primerljiv s tistim pri otrocih, ki so prvi odmerek prejeli v 12. mesecu starosti.
For the full list of all side effects reported with ProQuad, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi cepiva ProQuad, glejte navodilo za uporabo.
To protect against chickenpox, a second injection is needed, given one to three months after the first one; this can be done either by giving a second dose of ProQuad, or by giving a dose of another vaccine that only protects against chickenpox. 
Za zaščito pred noricami je potrebna druga injekcija, ki jo je treba dati od enega do tri mesece po prvem odmerku, pri čemer se lahko uporabi bodisi drugi odmerek zdravila ProQuad ali pa odmerek katerega drugega cepiva, ki ščiti samo pred noricami.
The Committee also recommended that the vaccine be authorised in children from nine to 12 months of age only in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common. 
Odbor je poleg tega priporočil, da se cepivo v določenih okoliščinah lahko uporablja tudi pri otrocih, ki so dopolnili devet do 12 mesecev, kot npr. v okviru nacionalnega programa cepljenja, ob izbruhu bolezni ali potovanju v kraje, kjer so ošpice pogost pojav.
For children above 12 months of age, one ProQuad injection is sufficient to provide optimal protection against measles, mumps and rubella. 
Pri otrocih, ki so stari več kot 12 mesecev, zadostuje ena injekcija cepiva ProQuad za optimalno zaščito proti ošpicam, mumpsu in rdečkam.
ProQuad is available as a powder and solvent that are made up into a suspension for injection. 
Na voljo je v obliki praška in vehikla za pripravo suspenzije za injiciranje.
ProQuad must not be used in children who are hypersensitive (allergic) to any chickenpox vaccine or measles, mumps or rubella vaccine, to any of the other ingredients, or to neomycin. 
Cepivo ProQuad se ne sme uporabljati pri otrocih, ki so preobčutljivi za (alergični na) katero koli cepivo proti noricam oziroma cepivo proti ošpicam, mumpsu in rdečkam, katero koli drugo sestavino zdravila ali na neomicin.
The main studies were carried out to look at the ability of one or two doses of the vaccine to trigger an immune response in 5,446 healthy children (aged 12 to 23 months). 
Glavne študije so bile izvedene pri 5 446 zdravih otrocih (starih od 12 do 23 mesecev), da bi proučili sposobnost sprožanja imunskega odziva z dajanjem enega ali dveh odmerkov cepiva.
ProQuad may also be given to children from nine months of age in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common. 
V določenih okoliščinah se daje tudi otrokom, ki so dopolnili devet mesecev starosti, npr. v okviru nacionalnega programa cepljenja, ob izbruhu bolezni ali pri potovanju v kraje, kjer so ošpice pogost pojav.
Why has ProQuad been approved? 
Zakaj je bilo zdravilo ProQuad odobreno?
ProQuad is given to children from 12 months of age to help protect them against the four diseases: measles, mumps, rubella, and chickenpox. 
Cepivo ProQuad se daje otrokom po dopolnjenem 12. mesecu starosti za zaščito pred naslednjimi štirimi boleznimi: ošpicami, mumpsom, rdečkami in noricami.
ProQuad contains weakened forms of the viruses that cause measles, mumps, rubella and chickenpox. 
Cepivo ProQuad vsebuje oslabljene oblike virusov, ki povzročajo ošpice, mumps, rdečke in norice.
ProQuad was compared with its ‘component vaccines', a triple vaccine against mumps, measles and rubella, and a vaccine against chickenpox. 
Cepivo ProQuad so primerjali s „sestavljenimi cepivi“, tj. trojnim cepivom proti mumpsu, ošpicam in rdečkam, ter cepivom proti noricam.
How has ProQuad been studied? 
Kako je bilo zdravilo ProQuad raziskano?
What is ProQuad used for? 
Za kaj se zdravilo ProQuad uporablja?
How does ProQuad work? 
Kako zdravilo ProQuad deluje?
How is ProQuad used? 
Kako se zdravilo ProQuad uporablja?
What is ProQuad? 
Kaj je zdravilo ProQuad?
ProQuad is a vaccine against measles, mumps, rubella, and varicella (chickenpox). 
Zdravilo ProQuad je cepivo proti ošpicam, mumpsu, rdečkam in noricam (vodenim kozam).
Measles, mumps, rubella and varicella vaccine (live) 
ProQuad cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
Children between nine and 12 months of age should receive a second dose at least three months after the first dose to ensure that they are adequately protected against measles and chickenpox. 
Da se zagotovi ustrezna zaščita pred ošpicami in noricami, morajo otroci, stari od 9 do 12 mesecev, drugi odmerek prejeti najmanj tri mesece po prvem odmerku.
Invented name Strength Pharmaceutical Form Route of Administration Packaging 
Številka EU Izmišljeno Ime Jakost Farmacevtska Oblika Pot Uporabe
Package size 
Velikost Pakiranja
Pre-filled syringe (glass) 3 ml (1 mg/ml) 4 pre-filled syringes l t o r 
4 napolnjene injekcijske brizge o ā
Pre-filled syringe (glass) 3 ml (1 mg/ml) 1 pre-filled syringe 
1 napolnjena injekcijska brizga
18 weeks. 
18 tednov
Date of first authorisation: 04 December 2013 Date of latest renewal: 20 November 2018 
Datum prve odobritve: 4. december 2013 Datum zadnjega podaljšanja: 20. november 2018
FFU*** 
FFE***
Age range as described in the protocol for the study. 
Starostni razpon kot je opisan v protokolu za študijo.
Small white particles may be present. 
Prisotni so lahko majhni beli delci.
This product contains genetically modified organisms (GMOs). 
To cepivo vsebuje gensko spremenjene organizme (GSO).
See section 5 for advice on storage and disposal. 
Glejte poglavje 5 za navodila o shranjevanju in odstranjevanju.
Each year the vaccine targets four strains of influenza, following the annual recommendations by the World Health Organisation. 
Cepivo vsako leto cilja na štiri seve virusa gripe v skladu z vsakoletnimi priporočili Svetovne zdravstvene organizacije.
*** fluorescent focus units. 
*** fluorescentna fokusna enota.
As a result, they replicate in the nasopharynx and induce protective immunity. 
Posledično se replicirajo v nazofarinksu in inducirajo zaščitno imunost.
See Table 1 and 2 for a summary of efficacy results in the paediatric population. 
Glejte preglednici 1 in 2 za povzetek rezultatov učinkovitosti v pediatrični populaciji.
Some side effects may be serious 
Nekateri neželeni učinki so lahko resni
For signs of allergic reactions, see section 4 “Possible side effects”. 
Za znake alergijskih reakcij glejte poglavje 4 ”Možni neželeni učinki”.
Number of study participants for year 1 efficacy analysis. 
Število preiskovancev v študiji v 1. letu analize učinkovitosti.
** produced in VERO cells by reverse genetic technology. 
** pridobljen v celicah VERO s tehnologijo reverzne genetike.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih
Read all of this leaflet carefully before the vaccine is given because it contains important information for you or your child. 
Preden prejmete to cepivo, natančno preberite navodilo, ker vsebuje pomembne podatke za vas ali vašega otroka!
Data presented for clinical trial D153-P504 are for study participants who received two doses of study vaccine. 
Podatki predstavljeni v klinični študiji D153-P504 so za preiskovance v študiji, ki so prejeli dva odmerka študijskega cepiva.
Do not inject. 
Ne injicirajte.
Stability data indicate that the vaccine components are stable for 12 hours when stored at temperatures from 8°C to 25°C. 
Podatki o stabilnosti kažejo, da so sestavine cepiva stabilne 12 ur, če je cepivo shranjeno pri temperaturi od 8 °C do 25 °C.
• if the child is less than 24 months of age. 
• če je otrok star manj kot 24 mesecev.
• if you have a blood disorder or a cancer that affects the immune system. 
• če imate krvno bolezen ali raka, ki vplivata na vaš imunski sistem.
Since 1985, two distinct lineages of influenza B viruses (Victoria and Yamagata) have circulated worldwide. 
Od leta 1985 sta v svetu znani dve liniji virusa gripe tipa B (Victoria in Yamagata).
• if you have ever had a severe allergic reaction to eggs or egg proteins. 
• če ste že kdaj imeli hudo alergijsko reakcijo na jajca oziroma jajčne beljakovine.
Four placebo-controlled studies included second season revaccination. 
Štiri s placebom kontrolirane študije so vključevale drugo sezonsko revakcinacijo.
Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 12 hours at a temperature not above 25°C. 
Pred uporabo lahko cepivo enkrat vzamete iz hladilnika za največ 12 ur pri temperaturi do 25 °C.
• severe allergic reaction: signs of a severe allergic reaction may include shortness of breath and swelling of the face or tongue. 
• huda alergijska reakcija: Znaki alergijske reakcije lahko vključujejo zasoplost in oteklost obraza ali jezika.
Influenza Season 
Sezona gripe
In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti cepiva ne smemo mešati z drugimi zdravili.
This is because of the risk of Reye's syndrome, a very rare but serious disease that can affect the brain and liver. 
To je zaradi tveganja Reyevega sindroma, zelo redke, vendar resne bolezni, ki lahko prizadane možgane in jetra.
M=months. 
a m = meseci b
• if you are allergic to gentamicin, gelatin or any of the other ingredients of this vaccine (listed in section 6 “Contents of the pack and other information”). 
• če ste alergični na gentamicin, na želatino ali katero koli sestavino tega cepiva (navedeno v poglavju 6 ”Vsebina pakiranja in dodatne informacije”).
Follow your doctor, nurse or pharmacist's instructions about if and when your child should return for the second dose. 
Upoštevajte navodila zdravnika, medicinske sestre ali farmacevta glede tega, če in kdaj naj se otrok vrne po drugi odmerek.
At the end of this period, Fluenz Tetra should be used immediately or discarded. 
Ob koncu tega obdobja je treba cepivo Fluenz Tetra uporabiti takoj ali ga zavreči.
None of the ingredients in the vaccine can cause the flu. 
Nobena sestavina cepiva ne more povzročiti gripe.
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. 
Za izboljšanje sledljivosti bioloških zdravil je treba jasno zabeležiti ime zdravila in številko serije uporabljenega zdravila.
Not all pack sizes may be available in your country. 
V vaši državi morda niso na voljo vsa navedena pakiranja.
(See also, How Fluenz Tetra is given, in section 3). 
(Glejte tudi Kako se aplicira cepivo Fluenz Tetra, poglavje 3).
• if you have been told by your doctor that you have a weakened immune system as a result of a disease, medicine or other treatment. 
• če vam je zdravnik povedal, da imate oslabljen imunski sistem kot posledico bolezni, zdravila, ki ga jemljete ali drugega načina zdravljenja.
* propagated in fertilised hens' eggs from healthy chicken flocks. 
* razmnožen v oplojenih kokošjih jajcih zdravih piščančjih jat.
Pharmacotherapeutic group: Influenza vaccines, influenza live attenuated; ATC Code: J07BB03 
Farmakoterapevtska skupina: cepiva proti gripi, oslabljen živ virus; oznaka ATC: J07BB03
If the vaccine has not been used after this 12 hour period, it should be discarded. 
Če zdravila v teh 12 urah ne porabite, ga morate zavreči.
Most hospitalisations were due to gastrointestinal and respiratory tract infections and occurred more than 6 weeks post vaccination. 
Največ hospitalizacij je bilo zaradi infekcij gastrointestinalnega in respiratornega trakta, ki so se pojavile več kot 6 tednov po cepljenju.
You do not need to actively inhale or sniff. 
Ni potrebno aktivno inhalirati ali vdihavati skozi nosnice.
Common: Pyrexia 
Pogosti: pireksija
Children less than 24 months of age should not receive this vaccine because of the risk of side effects. 
Otroci, mlajši od 24 mesecev, ne smejo prejeti tega cepiva zaradi tveganja neželenih učinkov.
• if you have severe asthma or are currently wheezing. 
• če imate hudo obliko astme ali trenutno sopete.
Vaccine recipients should attempt to avoid, whenever possible, close association with severely immunocompromised individuals (e.g. bone marrow transplant recipients requiring isolation) for 1-2 weeks following vaccination. 
Prejemniki cepiva morajo, kjer je to mogoče, preprečiti tesen stik s hudo imunsko oslabljenimi osebami (npr. prejemniki kostnega mozga, ki po presaditvi potrebujejo izolacijo) še 1 - 2 tedna po cepljenju.
The vaccine may contain residues of the following substances: egg proteins (e.g. ovalbumin) and gentamicin. 
Cepivo lahko vsebuje ostanke naslednjih snovi: jajčne beljakovine (npr. ovalbumin) in gentamicin.
Healthcare professionals are asked to report any suspected adverse reactions via national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
It is used in children and adolescents 24 months to less than 18 years of age. 
Uporablja se za otroke in mladostnike stare od 24 mesecev do manj kot 18 let.
Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) 
Pogostnosti neželenih učinkov so poročane kot: zelo pogosti (≥1/10) pogosti (≥1/100 do <1/10) občasni (≥1/1.000 do <1/100) redki (≥1/10.000 do <1/1.000) zelo redki (<1/10.000)
This is because of the risk of a very rare but serious disease (Reye's syndrome). 
Vzrok je v tveganju za zelo redko, a resno bolezen (Reyev sindrom).
• Do not use with a needle. 
• Ne uporabljajte z iglo.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements for medical waste. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi za medicinske odpadke.
• if you are already taking acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever). 
• če že jemljete acetilsalicilno kislino (snov, prisotna v številnih zdravilih za lajšanje bolečin in nižanje povišane telesne temperature).
Administration of influenza antiviral agents within two weeks of vaccination may affect the response of the vaccine. 
Uporaba protivirusnih zdravil proti gripi v roku dveh tednov po cepljenju lahko vpliva na odziv cepiva.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljena za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Fluenz Tetra Influenza vaccine 2019/2020 season 
Fluenz Tetra cepivo proti gripi sezona 2019/2020
Instructions for healthcare professionals 
Navodila za zdravstveno osebje
See section 6.6 for administration instructions. 
Glejte poglavje 6.6 za navodila o uporabi zdravila.
- This vaccine has been prescribed for you or your child only. 
- To cepivo je bilo predpisano vam ali vašemu otroku osebno in ga ne smete dajati drugim.
Your doctor, nurse or pharmacist will decide if Fluenz Tetra can be given at the same time as other vaccines. 
Zdravnik, farmacevt ali medicinska sestra se bo odločil, ali lahko prejmete cepivo Fluenz Tetra sočasno z drugimi cepivi.
• Do not give acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever) to children for 4 weeks after vaccination with Fluenz Tetra unless your doctor, nurse or pharmacist tells you otherwise. 
• Otrokom ne dajajte acetilsalicilne kisline (učinkovina, ki je prisotna v številnih zdravilih za lajšanje bolečin in nižanje povišane telesne temperature) še 4 tedne po cepljenju s cepivom Fluenz Tetra, razen če vam zdravnik, medicinska sestra ali farmacevt ne naročijo nasprotno.
The use of Fluenz Tetra should be based on official recommendations. 
Uporaba cepiva Fluenz Tetra mora temeljiti na uradnih priporočilih.
The immune response to rubella vaccine was significantly altered. 
Imunski odziv na cepivo proti rdečkam je bil značilno spremenjen.
• If you are pregnant, think you may be pregnant, plan to become pregnant soon or are breast-feeding, tell your doctor, nurse or pharmacist before receiving this vaccine. 
• če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden prejmete to cepivo.
The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml). 
Največja količina ovalbumina je manj kot 0,024 mikrograma na 0,2-mililitrski odmerek (0,12 mikrograma na ml).
A multicentre, randomised, double-blind, active-controlled, non-inferiority study was conducted to assess the immunogenicity of Fluenz Tetra compared to Fluenz (active control) in children and adolescents 2-17 years of age. 
Multicentrična, randomizirana, dvojno slepa, aktivna kontrolirana in neinferiorna študija je bila izvedena za ocenitev imunogenosti cepiva Fluenz Tetra v primerjavi s cepivom Fluenz (aktivna kontrola) pri otrocih in mladostnikih starih od 2 do 17 let.
Asia/ Oceania 
Azija/ Oceanija